{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:15:15Z","timestamp":1774530915761,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.leukres.2017.11.010","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T17:53:52Z","timestamp":1513360432000},"page":"12-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes"],"prefix":"10.1016","volume":"67","author":[{"given":"Pei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2017.11.010_bib0005","first-page":"963","article-title":"Transformation of myelodysplastic syndromes into acute myeloid leukemias","volume":"117","author":"Shi","year":"2004","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.leukres.2017.11.010_bib0010","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1056\/NEJMoa0912228","article-title":"Persistent malignant stem cells in del(5q) myelodysplasia in remission","volume":"363","author":"Tehranchi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.11.010_bib0015","first-page":"2034","article-title":"Expression of CD123 and CD114 on the bone marrow cells of the patients with myelodysplastic syndrome","volume":"123","author":"Yue","year":"2010","journal-title":"Chin. Med. J."},{"issue":"8","key":"10.1016\/j.leukres.2017.11.010_bib0020","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.leukres.2013.04.008","article-title":"CD47 is expressed abnormally on hematopoietic cells in myelodysplastic syndrome","volume":"37","author":"Jiang","year":"2013","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2017.11.010_bib0025","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cytogfr.2006.07.003","article-title":"Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system","volume":"17","author":"Kim","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"issue":"17","key":"10.1016\/j.leukres.2017.11.010_bib0030","doi-asserted-by":"crossref","first-page":"17ra9","DOI":"10.1126\/scitranslmed.3000349","article-title":"Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells","volume":"2","author":"Saito","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.leukres.2017.11.010_bib0035","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.leukres.2006.11.009","article-title":"Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference","volume":"31","author":"Valent","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2017.11.010_bib0040","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification ofmyeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.11.010_bib0045","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2017.11.010_bib0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1532\/IJH97.05144","article-title":"Biology of normal and acute myeloid leukemia stem cells","volume":"82","author":"Dick","year":"2005","journal-title":"Int. J. Hematol."},{"issue":"10","key":"10.1016\/j.leukres.2017.11.010_bib0055","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1007\/s00018-015-1846-x","article-title":"The inflammatory microenvironment in MDS","volume":"72","author":"Yang","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.leukres.2017.11.010_bib0060","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.stem.2016.08.021","article-title":"Mesenchymal inflammation drives genotoxic stress in hematopoietic stem cells and predicts disease evolution in human pre-leukemia","volume":"19","author":"Zambetti","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.leukres.2017.11.010_bib0065","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.leukres.2015.06.017","article-title":"Bone marrow niche in the myelodysplastic syndromes","volume":"39","author":"Cogle","year":"2015","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2017.11.010_bib0070","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","article-title":"Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy","volume":"153","author":"Aggarwal","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2017.11.010_bib0075","doi-asserted-by":"crossref","first-page":"e22654","DOI":"10.4161\/onci.22654","article-title":"Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes","volume":"2","author":"Mailloux","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.leukres.2017.11.010_bib0080","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2011.194","article-title":"Targeting immune dysregulation in myelodysplastic syndromes","volume":"305","author":"Olnes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.leukres.2017.11.010_bib0085","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2007-01-067546","article-title":"CD4\u202f+\u202fCD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)","volume":"110","author":"Kordasti","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2017.11.010_bib0090","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2017.11.010_bib0095","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/nm1483","article-title":"Targeting of CD44 eradicates human acute myeloid leukemic stem cells","volume":"12","author":"Jin","year":"2006","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.leukres.2017.11.010_bib0100","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2017.11.010_bib0105","doi-asserted-by":"crossref","first-page":"11008","DOI":"10.1073\/pnas.0704271104","article-title":"CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia","volume":"104","author":"Hosen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.leukres.2017.11.010_bib0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.leukres.2017.11.010_bib0115","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1073\/pnas.1100551108","article-title":"Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker[J]","volume":"108","author":"Jan","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.leukres.2017.11.010_bib0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.1991.tb07946.x","article-title":"Acute myeloid leukaemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor","volume":"77","author":"Macdonald","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2017.11.010_bib0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2350-10-22","article-title":"Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis","volume":"10","author":"Carr","year":"2009","journal-title":"BMC Med. Genet."},{"issue":"9","key":"10.1016\/j.leukres.2017.11.010_bib0130","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1038\/ng2102","article-title":"Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes","volume":"39","author":"Lowe","year":"2007","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.leukres.2017.11.010_bib0135","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/429843","article-title":"Localization of a type 1 diabetes locus in the IL2RA\/CD25 region by use of tag single-nucleotide polymorphisms","volume":"76","author":"Vella","year":"2005","journal-title":"Am. J. Hum. Genet."},{"issue":"9","key":"10.1016\/j.leukres.2017.11.010_bib0140","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa073493","article-title":"Risk alleles for multiple sclerosis identified by a genomewide study","volume":"357","author":"International Multiple Sclerosis Genetics C","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.leukres.2017.11.010_bib0145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2265.2007.02762.x","article-title":"Association of the interleukin-2 receptor alpha (IL-2Ralpha)\/CD25 gene region with Graves' disease using a multilocus test and tag SNPs","volume":"66","author":"Brand","year":"2007","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"10.1016\/j.leukres.2017.11.010_bib0150","doi-asserted-by":"crossref","first-page":"730380","DOI":"10.1155\/2014\/730380","article-title":"The Treg\/Th17 paradigm in lung cancer","volume":"2014","author":"Duan","year":"2014","journal-title":"J immunol res."},{"issue":"3","key":"10.1016\/j.leukres.2017.11.010_bib0155","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3892\/or.2013.2570","article-title":"Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters","volume":"30","author":"Li","year":"2013","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.leukres.2017.11.010_bib0160","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/sj.leu.2404497","article-title":"Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis","volume":"21","author":"Nakase","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2017.11.010_bib0165","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/sj.leu.2400836","volume":"11","author":"Paietta","year":"1997","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2017.11.010_bib0170","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00277-010-0994-1","article-title":"Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors","volume":"89","author":"Decker","year":"2010","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2017.11.010_bib0175","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.ejca.2009.02.021","article-title":"Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML","volume":"45","author":"Terwijn","year":"2009","journal-title":"Eur. J. Cancer (Oxford, England : 1990)"},{"issue":"6","key":"10.1016\/j.leukres.2017.11.010_bib0180","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2017.11.010_bib0185","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2011-02-337725","article-title":"Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia","volume":"117","author":"Buyse","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.11.010_bib0190","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1038\/bcj.2014.9","article-title":"Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine","volume":"4","author":"Miltiades","year":"2014","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T21:54:46Z","timestamp":1751147686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"alternative-id":["S0145212617305969"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.11.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}